Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Oxytetracycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.69 |
| ▸ | MEN1 | O00255 | 9/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.69 |
| ▸ | USP2 | O75604 | 7/20 | 0.69 |
| ▸ | HPGD | P15428 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | RECQL | P46063 | 5/20 | 0.69 |
| ▸ | THRB | P10828 | 4/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxytetracycline SCHEMBL2806490 | 0.99 | TDP1 (0.69) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782617 | 0.99 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL18048891 | 0.99 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL2899 | 0.99 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL2614977 | 0.99 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL1292896 | 0.99 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL5507247 | 0.99 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL21133472 | 0.99 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL21133474 | 0.99 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782519 | 0.99 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 696 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| CN-109874922-B | Feed containing hermetia illucens and capable of improving growth performance of piglets | 温氏食品集团股份有限公司 | 2022-12-16 | — | — | CN | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| CN-114557408-A | Pet dog feed capable of actively digesting and preventing diseases after being eaten | 郑丽群 | 2022-05-31 | — | — | CN | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| CN-108208315-B | Piglet nursing feed for preventing and treating diarrhea and improving growth speed and preparation method thereof | 宋立臣 | 2021-07-13 | — | — | CN | claimed |
| CN-108432949-B | Energy-saving and environment-friendly oxytetracycline calcium production equipment and preparation method | 河北圣雪大成制药有限责任公司 | 2021-06-18 | — | — | CN | claimed |
| CN-111955613-A | Functional pig compound feed composition and growing-finishing pig feeding method | 中粮营养健康研究院有限公司 | 2020-11-20 | — | — | CN | claimed |
| US-20090111780-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EAR CANAL INFECTION AND INFLAMMATION | EVERETT LABORATORIES, INC. | 2009-04-30 | — | — | US | claimed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | claimed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | claimed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| CN-1539313-A | Full lemon branches mixed feedstuff for lamb | 宁夏农林科学院沙漠治理研究所 | 2004-10-27 | — | — | CN | claimed |
| CN-1539312-A | Full lemon branches mixed feedstuff for full mouth sheep | 宁夏农林科学院沙漠治理研究所 | 2004-10-27 | — | — | CN | claimed |
| US-6761899-B1 | DUSTLESS, CONTAINING TETRACYCLINE DERIVATIVE | PENNFIELD OIL COMPANY | 2004-07-13 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | TDP1 1258/4885MEN1 3114/4885KMT2A 4574/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | TDP1 1276/4885MEN1 1014/4885KMT2A 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.